An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis

Journal of Internal Medicine

Volumn 256, Issue 1, 2004, Pages 63-69

  Ormarsdottir S ^a,d   Mallmin, H ^a   Naessen T ^a   Petren Mallmin M ^a   Broome U ^b   Hultcrantz, R ^b   Loof L ^c  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c CENTRAL HOSPITAL   (Sweden)

^d Icelandic Medicines Control Agency   (Sweden)

Author keywords

Biliary; Bone density; Hormone replacement therapy; Liver cirrhosis; Oestrogen; Osteoporosis

Indexed keywords

ALFACALCIDOL; AMINOTRANSFERASE; BIOCHEMICAL MARKER; CALCIUM; CALCIUM GLUBIONATE; ESTRADIOL; MEDROXYPROGESTERONE; MEDROXYPROGESTERONE ACETATE; RECOMBINANT HORMONE; VITAMIN D;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BONE DENSITY; BONE MINERAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; HORMONE SUBSTITUTION; HUMAN; INTERMETHOD COMPARISON; LUMBAR SPINE; MALE; MEDICAL ASSESSMENT; METABOLIC RATE; MULTICENTER STUDY; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; PREVALENCE; PREVENTIVE MEDICINE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; VITAMIN SUPPLEMENTATION;

ADULT; AGED; ALKALINE PHOSPHATASE; BILIRUBIN; BIOLOGICAL MARKERS; BONE DENSITY; CALCIUM; DRUG THERAPY, COMBINATION; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; FEMUR NECK; HORMONE REPLACEMENT THERAPY; HUMANS; HYDROXYCHOLECALCIFEROLS; LIVER; LIVER CIRRHOSIS, BILIARY; LUMBAR VERTEBRAE; MEDROXYPROGESTERONE; MIDDLE AGED; OSTEOPOROSIS; STATISTICS, NONPARAMETRIC; TRANSAMINASES;

EID: 19244366499     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2004.01342.x     Document Type: Article

References (38)

1. Scheuer P. Primary biliary cirrhosis. Proc R Soc Med 1967; 60: 1257-60.
2. Sherlock S, Scheuer PJ. The presentation and diagnosis of 100 patients with primary biliary cirrhosis. N Engl J Med 1973; 289: 674-8.
3. Neuberger J. Primary biliary cirrhosis. Lancet 1997; 350: 875-9.
4. Bonkovsky HL, Hawkins M, Steinberg K et al. Prevalence and prediction of osteopenia in chronic liver disease. Hepatology 1990; 12: 273-80.
5. Guanabens N, Pares A, Marinoso L et al. Factors influencing the development of metabolic bone disease in primary biliary cirrhosis. Am J Gastroenterol 1990; 85: 1356-62.
6. Newton J, Francis R, Prince M et al. Osteoporosis in primary biliary cirrhosis revisited. Gut 2001; 49: 282-7.
7. Le Gars L, Grandpierre C, Chazouilleres O, Berenbaum F, Poupon R. Bone loss in primary biliary cirrhosis: absence of association with severity of liver disease. Joint Bone Spine 2002; 69: 195-200.
8. Eastell R, Dickson ER, Hodgson SF et al. Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis. Hepatology 1991; 14: 296-300.
9. Ormarsdottir S, Ljunggren O, Mallmin H, Olsson R, Prytz H, Loof L. Longitudinal bone loss in postmenopausal women with primary biliary cirrhosis and well-preserved liver function. J Intern Med 2002; 252: 537-41.
10. Shih MS, Anderson C. Does 'hepatic osteodystrophy' differ from peri- and postmenopausal osteoporosis? A histomorphometric study. Calcif Tissue Int 1987; 41: 187-91.
11. Mitchison HC, Malcolm AJ, Bassendine MF, James OF. Metabolic bone disease in primary biliary cirrhosis at presentation. Gastroenterology 1988; 94: 463-70.
12. Hodgson SF, Dickson ER, Eastell R, Eriksen EF, Bryant SC, Riggs BL. Rates of cancellous bone remodeling and turnover in osteopenia associated with primary biliary cirrhosis. Bone 1993; 14: 819-27.
13. Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology 2000; 31: 1005-13.
14. Wolfhagen FH, van Buuren HR, Vleggaar FP, Schalm SW. Management of osteoporosis in primary biliary cirrhosis. Baillieres Best Pract Res Clin Gastroenterol 2000; 14: 629-41.
15. Levy C, Lindor KD. Treatment options for primary biliary cirrhosis and primary sclerosing cholangitis. Curr Treat Options Gastroenterol 2003; 6: 93-103.
16. Menon KV, Angulo P, Boe GM, Lindor KD. Safety and efficacy of estrogen therapy in preventing bone loss in primary biliary cirrhosis. Am J Gastroenterol 2003; 98: 889-92.
17. Guanabens N, Pares A, Monegal A et al. Etidronate versus fluoride for treatment of osteopenia in primary biliary cirrhosis: preliminary results after 2 years. Gastroenterology 1997; 113: 219-24.
18. Lindor KD, Jorgensen RA, Tiegs RD, Khosla S, Dickson ER. Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial. J Hepatol 2000; 33: 878-82.
19. Crippin JS, Jorgensen RA, Dickson ER, Lindor KD. Hepatic osteodystrophy in primary biliary cirrhosis: effects of medical treatment. Am J Gastroenterol 1994; 89: 47-50.
20. Olsson R, Mattsson LA, Obrant K, Mellstrom D. Estrogen-progestogen therapy for low bone mineral density in primary biliary cirrhosis. Liver 1999; 19: 188-92.
21. Van Erpecum KJ, Van Berge Henegouwen GP, Verschoor L, Stoelwinder B, Willekens FL. Different hepatobiliary effects of oral and transdermal estradiol in postmenopausal women. Gastroenterology 1991; 100: 482-8.
22. Ansbacher R. The pharmacokinetics and efficacy of different estrogens are not equivalent. Am J Obstet Gynecol 2001; 184: 255-63.
23. Vongpatanasin W, Tuncel M, Wang Z, Arbique D, Mehrad B, Jialal I. Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women. J Am Coll Cardiol 2003; 41: 1358-63.
24. Ribot C, Tremollieres F, Pouilles JM, Louvet JP, Peyron R. Preventive effects of transdermal administration of 17 beta-estradiol on postmenopausal bone loss: a 2-year prospective study. Gynecol Endocrinol 1989; 3: 259-67.
25. Lufkin EG, Wahner HW, O'Fallon WM et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992; 117: 1-9.
26. Hillard TC, Whitcroft SJ, Marsh MS et al. Long-term effects of transdermal and oral hormone replacement therapy on postmenopausal bone loss. Osteoporos Int 1994; 4: 341-8.
27. Isoniemi H, Appelberg J, Nilsson CG, Makela P, Risteli J, Hockerstedt K. Transdermal oestrogen therapy protects postmenopausal liver transplant women from osteoporosis. A 2-year follow-up study. J Hepatol 2001; 34: 299-305.
28. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.
29. WHO. Assessment of Fracture Risk and its Application to Screening for Postmenopausal Osteoporosis. Geneva: World Health Organization Technical Report Series, 1994; 843.
30. Guanabens N, Pares A, del Rio L et al. Sodium fluoride prevents bone loss in primary biliary cirrhosis. J Hepatol 1992; 15: 345-9.
31. Appelberg J, Isoniemi H, Nilsson CG, Hockerstedt K, Ylostalo P. Safety and efficacy of transdermal estradiol replacement therapy in postmenopausal liver transplanted women. A preliminary report. Acta Obstet Gynecol Scand 1998; 77: 660-4.
32. Smith RN, Studd JW, Zamblera D, Holland EF. A randomised comparison over 8 months of 100 micrograms and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. Br J Obstet Gynaecol 1995; 102: 475-84.
33. Gambacciani M, Ciaponi M, Cappagli B, Genazzani AR. Effects of low-dose continuous combined conjugated estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmenopausal women. Am J Obstet Gynecol 2001; 185: 1180-5.
34. Felsenberg D, Alenfeld F, Bock O, Hammermeister C, Gowan W. Placebo-controlled multicenter study of oral alendronate in postmenopausal osteoporotic women. FOSIT-Study-Group. Fosamax International Trial. Maturitas 1998; 31: 35-44.
35. Pols HA, Felsenberg D, Hanley DA et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Foxamax International Trial Study Group. Osteoporos Int 1999; 9: 461-8.
36. Chlebowski RT, Hendrix SL, Langer RD et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy post-menopausal women. The women's health initiative randomized trial. JAMA 2003; 289: 3243-53.
37. Million Women Study collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419-27.
38. Verma A, Jazrawi RP, Ahmed HA, Northfield TC. Prescribing habits in primary biliary cirrhosis: a national survey. Eur J Gastroenterol Hepatol 1999; 11: 817-20.